Literature DB >> 25263447

p53 protein aggregation promotes platinum resistance in ovarian cancer.

Y Yang-Hartwich1, M G Soteras1, Z P Lin2, J Holmberg1, N Sumi1, V Craveiro1, M Liang1, E Romanoff1, J Bingham1, F Garofalo1, A Alvero1, G Mor1.   

Abstract

High-grade serous ovarian carcinoma (HGSOC), the most lethal gynecological cancer, often leads to chemoresistant diseases. The p53 protein is a key transcriptional factor regulating cellular homeostasis. A majority of HGSOCs have inactive p53 because of genetic mutations. However, genetic mutation is not the only cause of p53 inactivation. The aggregation of p53 protein has been discovered in different types of cancers and may be responsible for impairing the normal transcriptional activation and pro-apoptotic functions of p53. We demonstrated that in a unique population of HGSOC cancer cells with cancer stem cell properties, p53 protein aggregation is associated with p53 inactivation and platinum resistance. When these cancer stem cells differentiated into their chemosensitive progeny, they lost tumor-initiating capacity and p53 aggregates. In addition to the association of p53 aggregation and chemoresistance in HGSOC cells, we further demonstrated that the overexpression of a p53-positive regulator, p14ARF, inhibited MDM2-mediated p53 degradation and led to the imbalance of p53 turnover that promoted the formation of p53 aggregates. With in vitro and in vivo models, we demonstrated that the inhibition of p14ARF could suppress p53 aggregation and sensitize cancer cells to platinum treatment. Moreover, by two-dimensional gel electrophoresis and mass spectrometry we discovered that the aggregated p53 may function uniquely by interacting with proteins that are critical for cancer cell survival and tumor progression. Our findings help us understand the poor chemoresponse of a subset of HGSOC patients and suggest p53 aggregation as a new marker for chemoresistance. Our findings also suggest that inhibiting p53 aggregation can reactivate p53 pro-apoptotic function. Therefore, p53 aggregation is a potential therapeutic target for reversing chemoresistance. This is paramount for improving ovarian cancer patients' responses to chemotherapy, and thus increasing their survival rate.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25263447     DOI: 10.1038/onc.2014.296

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  55 in total

Review 1.  Autophagy gone awry in neurodegenerative diseases.

Authors:  Esther Wong; Ana Maria Cuervo
Journal:  Nat Neurosci       Date:  2010-07       Impact factor: 24.884

2.  Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.

Authors:  Jie Xu; Joke Reumers; José R Couceiro; Frederik De Smet; Rodrigo Gallardo; Stanislav Rudyak; Ann Cornelis; Jef Rozenski; Aleksandra Zwolinska; Jean-Christophe Marine; Diether Lambrechts; Young-Ah Suh; Frederic Rousseau; Joost Schymkowitz
Journal:  Nat Chem Biol       Date:  2011-03-27       Impact factor: 15.040

3.  P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2.

Authors:  W Tao; A J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

4.  Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.

Authors:  Siân Rizzo; Jenny M Hersey; Paul Mellor; Wei Dai; Alessandra Santos-Silva; Daniel Liber; Louisa Luk; Ian Titley; Craig P Carden; Garry Box; David L Hudson; Stanley B Kaye; Robert Brown
Journal:  Mol Cancer Ther       Date:  2011-01-07       Impact factor: 6.261

5.  Correlations of partial and extensive methylation at the p14(ARF) locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors.

Authors:  S Zheng; P Chen; A McMillan; A Lafuente; M J Lafuente; A Ballesta; M Trias; J K Wiencke
Journal:  Carcinogenesis       Date:  2000-11       Impact factor: 4.944

6.  Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells.

Authors:  R Chen; A B Alvero; D A Silasi; M G Kelly; S Fest; I Visintin; A Leiser; P E Schwartz; T Rutherford; G Mor
Journal:  Oncogene       Date:  2008-04-14       Impact factor: 9.867

7.  Stem-like ovarian cancer cells can serve as tumor vascular progenitors.

Authors:  Ayesha B Alvero; Han-Hsuan Fu; Jennie Holmberg; Irene Visintin; Liora Mor; Carlos Cano Marquina; Jessica Oidtman; Dan-Arin Silasi; Gil Mor
Journal:  Stem Cells       Date:  2009-10       Impact factor: 6.277

8.  Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity.

Authors:  Cristian A Lasagna-Reeves; Audra L Clos; Diana Castillo-Carranza; Urmi Sengupta; Marcos Guerrero-Muñoz; Brent Kelly; Richard Wagner; Rakez Kayed
Journal:  Biochem Biophys Res Commun       Date:  2012-12-19       Impact factor: 3.575

9.  Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment.

Authors:  Vinicius Craveiro; Yang Yang-Hartwich; Jennie C Holmberg; Won Duk Joo; Natalia J Sumi; John Pizzonia; Brian Griffin; Sabrina K Gill; Dan-Arin Silasi; Masoud Azodi; Thomas Rutherford; Ayesha B Alvero; Gil Mor
Journal:  Cancer Med       Date:  2013-08-27       Impact factor: 4.452

10.  cDNA sequencing improves the detection of P53 missense mutations in colorectal cancer.

Authors:  Malgorzata Szybka; Magdalena Zakrzewska; Piotr Rieske; Grazyna Pasz-Walczak; Dominika Kulczycka-Wojdala; Izabela Zawlik; Robert Stawski; Dorota Jesionek-Kupnicka; Pawel P Liberski; Radzislaw Kordek
Journal:  BMC Cancer       Date:  2009-08-11       Impact factor: 4.430

View more
  47 in total

Review 1.  Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.

Authors:  Khalid El Bairi; Abdul Hafeez Kandhro; Adel Gouri; Wafaa Mahfoud; Noureddine Louanjli; Brahim Saadani; Said Afqir; Mariam Amrani
Journal:  Cell Oncol (Dordr)       Date:  2016-12-15       Impact factor: 6.730

2.  Sulfated glycosaminoglycans mediate prion-like behavior of p53 aggregates.

Authors:  Naoyuki Iwahashi; Midori Ikezaki; Taro Nishikawa; Norihiro Namba; Takashi Ohgita; Hiroyuki Saito; Yoshito Ihara; Toshinori Shimanouchi; Kazuhiko Ino; Kenji Uchimura; Kazuchika Nishitsuji
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-14       Impact factor: 11.205

3.  New Insights into the Multivariate Analysis of SER Spectra Collected on Blood Samples for Prostate Cancer Detection: Towards a Better Understanding of the Role Played by Different Biomolecules on Cancer Screening: A Preliminary Study.

Authors:  Vlad Cristian Munteanu; Raluca Andrada Munteanu; Diana Gulei; Radu Mărginean; Vlad Horia Schițcu; Anca Onaciu; Valentin Toma; Gabriela Fabiola Știufiuc; Ioan Coman; Rareș Ionuț Știufiuc
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

Review 4.  Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?

Authors:  Danielly C F Costa; Guilherme A P de Oliveira; Elio A Cino; Iaci N Soares; Luciana P Rangel; Jerson L Silva
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-10-03       Impact factor: 10.005

Review 5.  Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer.

Authors:  Xin Yu; Heyi Zheng; Matthew Tv Chan; William Kk Wu
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

6.  Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response.

Authors:  A N van den Pol; X Zhang; E Lima; M Pitruzzello; N Albayrak; A Alvero; J N Davis; G Mor
Journal:  Virology       Date:  2020-11-12       Impact factor: 3.616

Review 7.  Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.

Authors:  Guilherme A P de Oliveira; Luciana P Rangel; Danielly C Costa; Jerson L Silva
Journal:  Front Oncol       Date:  2015-04-29       Impact factor: 6.244

8.  Variable Mutations at the p53-R273 Oncogenic Hotspot Position Leads to Altered Properties.

Authors:  Ankush Garg; Jagadish Prasad Hazra; Malay Kumar Sannigrahi; Sabyasachi Rakshit; Sharmistha Sinha
Journal:  Biophys J       Date:  2019-12-21       Impact factor: 4.033

9.  Metallodrug-protein interaction probed by synchrotron terahertz and neutron scattering spectroscopy.

Authors:  Luis Alberto Esteves Batista de Carvalho; Adriana Pereira Mamede; Ana Lucia Marques Batista de Carvalho; Joana Marques; Gianfelice Cinque; Svemir Rudić; Maria Paula Matos Marques
Journal:  Biophys J       Date:  2021-06-30       Impact factor: 3.699

Review 10.  Role of p53 isoforms and aggregations in cancer.

Authors:  SeJin Kim; Seong Soo A An
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.